Global Neurostimulation Device Market – Analysis, Development, Growth Factor, Size, Share, and Forecast 2024, Boston Scientific Corporation, Cyberonics, Inc., Nevro Corporation, Neurosigma, Inc.,

Neurostimulation is the technology to delivery low voltage electricity to a specific nerve or target in the spinal cord or brain to affect neuronal transmission. It is a therapeutic tool used to treat neuropathic pain or to modulate motor function and for a range of different diseases such as epilepsy, migraine, and Parkinson’s disease. The global neurostimulation device market is growing at significant rate due to increasing prevalence of neurological diseases and growing geriatric population. The market has witnessed high demand for internal neurostimulation over the last few years, due to the increasing prevalence of neurological disorders.

Download Free Report Sample at: https://www.vynzresearch.com/healthcare/neurostimulation-device-market/request-sample

The lack of trained professionals and unfavorable reimbursement scenario are the major challenges for the growth of neurostimulation device market. In addition, availability of alternative options of treatment for neurological disorders and side effects and risks associated with neurostimulation therapy are also some of the factors hindering the growth of the market.

The key challenge for the new entrants is the survival in capital intensive and highly regulated neurostimulation device market. However, various large neurostimulation companies can enter the neurostimulation device market through mergers and acquisitions of smaller companies.

Geographically, North America is the largest neurostimulation device market as the region has increasing prevalence of chronic diseases and growing geriatric population. For instance, according to Centers for Disease Control and Prevention (CDC), in 2015 approximately 23.1 million people in the U.S. had diabetes. In addition according to National Institutes of Health, in the U.S. approximately one million people have Parkinson’s disease. As per the Alzheimer's Association in 2017, 5.5 million Americans had Alzheimer and about 5.3 million of this patient population’s age was 65 years or more. In addition, according to Alzheimer's Association approximately 14 million people are expected to suffer from Alzheimer in 2050.

Explore Full Report Description at: https://www.vynzresearch.com/healthcare/neurostimulation-device-market

Asia-Pacific is observed to witness the fastest growth in the market. Largest population, increasing prevalence of diabetes, growing geriatric population and rising adoption of neurostimulation devices is creating a positive impact on the neurostimulation device market growth in the region.

Key players in the neurostimulation device industry are investing in the development of innovative and advance neurostimulation device products, which is strengthening their position in the market. In September 2017, Medtronic, Inc. received FDA approval and launched the Intellis platform for the management of certain types of chronic intractable pain. Medtronic, Inc., Boston Scientific Corporation, Cyberonics, Inc., Nevro Corporation, Neurosigma, Inc., Neuropace, Inc., Coclear Ltd., St. Jude Medical Inc., LivaNova PLC, Aleva Neurotherapeutics SA, Synapse Biomedical, Inc., Neuronetics, Inc. are some of the key players offering neurostimulation devices.

About VynZ Research : 

VynZ Research is an innovative market research and competitive intelligence company with global competences. We have helped several customers to develop their strategy and make better business decisions by providing actionable intelligence through market research report.

Contact

VynZ Research USA

165 Broadway, 23rd Floor,
New York City, New York – 10006
United States of America
Toll-Free:1-888-253-3960
Email: support@vynzresearch.com
Website: https://www.vynzresearch.com
Connect With us: Linkedin | Twitter | Facebook | Google+

This release was published on openPR.